Data publicly released to the global research community from the largest proteomics study on COVID-19 – a collaboration between Massachusetts General Hospital and Olink

Olink is proud and delighted to announce its contribution to one of the largest longitudinal COVID-19 proteomics studies to date, together with the prestigious Massachusetts General Hospital (MGH). Working with the outstanding research team from MGH, protein measurements and associated clinical data have been made available via the Olink company website.

This landmark study is part of the “COVID-19 Technology Access Framework” initiative, which was started early in the pandemic by Harvard, MIT, Stanford and the Broad institute. This aims to combine data from the most critically important technologies that may help prevent, diagnose, or treat COVID-19 infections, and to share the findings openly to accelerate research, inform the public health response and help save lives.

In collaboration with Olink, a team from MGH rapidly profiled over 1400 proteins in a cohort of COVID-19 patients using the recently launched Olink® Explore 1536 platform to look for new protein biomarkers useful for preventing, diagnosing and treating COVID-19 infection. The extensive dataset, with over 1.3 million protein data points and essential clinical parameters from the study, is now freely available for everyone to access through the Olink website, to stimulate and facilitate further investigation of the pathways underlying severe disease that may be the basis for early diagnosis and clinical intervention.

For more details of this important COVID-19 study, and to access the data, please GO TO THE STUDY PAGE

Olink continues to support the global research community in the fight against the pandemic and is offering special pricing on protein biomarker studies related to COVID-19 to assist in this effort - see details here.

“We are immensely proud of our contribution to one of the largest longitudinal COVID-19 studies which will help to rapidly identify the proteins and pathways involved in COVID-19 and to better understand the disease and its treatment. We are very excited about the preliminary analysis from this groundbreaking study and encouraged by the strong biomarker findings identified showing strong associations to disease severity as well as proteins predicting outcome at baseline”, says Dr. Ida Grundberg, Chief Scientific Officer, Olink Proteomics.

“We are grateful to have entered this collaborative effort with Olink Proteomics to investigate the plasma proteomic signatures of COVID-19 patients and with Olink’s help have profiled over 1400 plasma proteins in our entire cohort. We hope together we can provide the clinical and scientific community with a rich dataset for further investigation of pathways underlying severe disease that may be the basis for early diagnosis and clinical intervention. As such, we are eager to share our data broadly with the scientific community to augment others’ findings and to accelerate discovery that may lead to new therapies and a better understanding of the underpinnings of COVID-19.” says Dr. Michael R. Filbin, Department of Emergency Medicine, Massachusetts General Hospital.

Contact:

Dr. Ida Grundberg

Email: ida.grundberg@olink.com

Cell: +46 733 53 70 05